LAKE FOREST, CA – March 5, 2015 — Cryoport, Inc. (OTC BB: CYRX) ("the Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that Broekman Logistics will support Cyroport’s Operations Center in Singapore, responding to Cryoport’s rapidly expanding client base in Asia. Broekman currently supports Cryoport’s European Operations Center, ensuring a seamless faciliation of Cryoport’s solutions for global life sciences clients.
Broekman Logistics provides secure and full-service warehousing facilities for distribution and shipping, as well as broker services covering the entire Asian region. In addition, Broekman is a Customs-Trade Partnership Against Terrorism (C-TPAT) and Authorized Economic Operator (AEO) with worldwide certification and is a value-added and complementary logistics provider to Cryoport.
Under the arrangement, Broekman works with Cryoport’s logistics professionals to assist in delivering Cryoport’s solutions to its global clients. The arrangement is inclusive of all solutions and support, beginning with order entry to order fulfillment, monitoring, quality testing, cleaning, and maintenance of Cryoport Express® solutions. Central to Cryoport’s global solutions offering is the CryoportalTM, the cloud-based operating platform where orders are entered and managed throughout the solutions’ cycles. Cryoport’s Asian clients will benefit from Broekman’s professional services and excellent track record.
Jerrell Shelton, Chief Executive Officer of Cryoport, stated, “We are pleased to expand our relationship with Broekman into Asia. Broekman is the ideal partner to assist us in carrying out our mission of reliable service to the life sciences industry in Asia. The opportunities that exist in this region of the world are sizable and growing rapidly. Broekman’s international presence and comprehensive logistics expertise will help drive much broader awareness of our cryogenic logistics solutions. They will be crucial to helping Cryoport meet the market demands of our life sciences clients.”
Jacques Kleinkramer, Managing Director, Broekman Logistics Division, stated, "We are delighted to be partnered with Cryoport and to help support its growing client base and business in Asia with its validated cryogenic logistics solutions for the life sciences industry. The spike in need for safe and controlled shipments of temperature-sensitive commodities, within a framework of strict regulations and procedures, is being addressed by Cryoport in a comprehensive manner. We look forward to helping Cryoport build on its foothold in the cryogenic logistics market.”
About Broekman Logistics
Broekman Logistics is a world-leading provider of full-service, complex, tailor-made logistics solutions. Established in 1960 in Rotterdam, where it is still headquartered, Broekman has continued to expand and develop, building on the reliability, flexibility and broad logistics expertise for which it is now well known. It has built up an excellent reputation in forwarding and shipping, warehousing and distribution, and break bulk.
Broekman Logistics employs more than 800 staff in the Netherlands, Belgium, the Czech Republic, Poland, India, Singapore and China. Its excellent contacts and local market knowledge enable it to deliver outstanding and consistently reliable service to its customers. For more information, please visit www.broekmanlogistics.com.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Statements in this press release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2014. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise, any forward-looking statements in this press release.